Clarity Pharmaceuticals (CU6) Q4 2025 TU earnings summary

Executive summary

• Achieved significant clinical milestones across all core programs, including progression of late-stage trials and positive topline data in prostate and neuroendocrine cancer diagnostics and therapeutics.

• Completed a $203 million institutional placement at a premium, strengthening the balance sheet and supporting ongoing clinical and commercial activities.

• Prioritised high-potential programs and streamlined portfolio, closing lower-priority trials to focus on key assets in prostate, neuroendocrine, and breast cancers.

• Expanded manufacturing and supply chain capabilities with new agreements to ensure large-scale, reliable access to copper isotopes and lead products in the US.

Financial highlights

• Cash balance at 30 June 2025 was $84.1 million, with net operating cash outflows of $9.1 million for the quarter, reduced by a $11.1 million R&D tax incentive received.

• Pro-forma cash balance post-placement is approximately $288 million, providing substantial funding for ongoing and future programs.

• R&D expenditure for the quarter was $15.9 million, reflecting increased clinical activity, especially with the AMPLIFY trial commencement.

• No material variances in use of funds compared to prior guidance; related party payments for the quarter totaled $705,744.

Outlook and guidance

• Well-funded to progress late-stage clinical trials and commercialisation, with estimated nine quarters of funding available at current cash burn rates.

• Focused on advancing SAR-bisPSMA, SARTATE, and SAR-Bombesin programs toward regulatory approval and commercial launch.

• Ongoing discussions with the US FDA for Phase III and registration pathways for lead diagnostic and therapeutic agents.